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doi:10.1016/j.ejvs.2008.12.002Abstract Objectives: Definitive evidence that red blood cell transfusion improves outcome
after vascular surgery is lacking. The aims of the study were to determine, among stable
consecutive patients who underwent elective major vascular surgery, (1) the association
between postoperative transfusion and 30-day death, myocardial infarction, and both, and
(2) and if this association differs according to the presence of postoperative anaemia (haemo-
globin value less than 9.0 g/dL within 7 days after surgery).
Methods: A retrospective observational study was conducted on 359 patients prospectively
screened according to the ACC/AHA guidelines for preoperative risk in non-cardiac surgery.
Main outcome was 30-day death; secondary outcomes 30-day myocardial infarction, and
composite of 30-day myocardial infarction or death.
Results: Of the patients included, 95 (26.5%) received at least one unit of red blood cells.
Patients who received transfusion had a significantly increased hazard of 30-day death (hazard
ratio [HR] 11.72, 95% confidence interval [CI] 3.92e35.10; p < 0.0001), myocardial infarction
(HR 3.3, 95% CI 1.7e6.1; pZ 0.0003), and both (HR 4.0 95% CI 2.2e7.3; p < 0.0001). Such asso-
ciations held even after adjusting for baseline characteristics, surgical risk, bleeding, and
propensity to receive transfusion. There was a significant interaction between transfusion
and postoperative anaemia (pZ 0.012). In patients without anaemia, transfusion wasCardiology, Policlinico University Hospital, Modena and Reggio Emilia University, Via del Pozzo 71,
9 7452; fax: þ39 059 422 4498.
re.it (L. Politi).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
312 F. Bursi et al.associated with higher risk of 30-day death (HR 19.20, 95% CI 3.99e92.45; pZ 0.007), myocar-
dial infarction (HR 5.05, 95% CI 2.23e11.44; pZ 0.0001), and both. Conversely, in patients
with anaemia this association was not significant.
Conclusions: In patients who underwent elective major vascular surgery, perioperative trans-
fusion was associated with a significantly increased risk of 30-day events which was more
attributable to patients with lesser degree of anaemia. Our data caution against the use of
liberal transfusion in stable vascular surgery patients.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Anaemia occurs frequently after vascular surgery1 and
usually results in red blood cell transfusion (RBT).2 Allo-
genic RBT is a finite3 and expensive4 resource, and its use
can be associated with a risk for infection and transfusion
reactions.5 Thus, there has been concern that if transfusion
policies are too liberal, they could result in excess
morbidity and mortality.6 Although these risks are well
reported and have led to a re-evaluation of the criteria for
the use of blood products,5 a significant proportion of
practitioners have not modified their approach because of
fear of the mortality and morbidity related to anaemia,
especially in patients with coronary artery disease.7 It is
clear that anaemia is less tolerated in older patients8 and in
patients with coronary disease3,9 undergoing coronary
artery bypass graft surgery.10 Although RBT should increase
tissue oxygenation in patients with coronary artery
disease,11 the data concerning the effectiveness of this
approach are controversial.6,12,13 This riskebenefit rela-
tionship is of particular importance in patients who undergo
major vascular surgical procedures. Thus, whether these
putative benefits are greater than the risks associated with
RBT in anaemic stable patients during vascular surgery is
not known. Accordingly, the aims of this study were to
assess, among consecutive stable patients who underwent
major vascular surgery, (1) the association between RBT
and events through 30 days, including death, myocardial
infarction, and the composite of death or myocardial
infarction, and (2) to assess if the association between RBT
and events differs in relation to the severity of the
anaemia.
Methods
We studied 359 consecutive patients who were admitted to
our Institution for elective major vascular surgery. Before
surgery all patients were prospectively screened according
to the ACC/AHA guidelines for preoperative evaluation of
cardiac risk in non-cardiac surgery14 as previously described
by our group.15 We included only patients referred for
elective open vascular surgery who could not be unstable or
have major clinical cardiovascular risk predictors (unstable
coronary syndromes, decompensated heart failure, signifi-
cant arrhythmias, and severe valve disease). Data were
provided by review of hospital charts, which was assessed
by two independent investigators (L.P. and T.G.). We
excluded patients who had haemorrhagic hypovolaemic
shock requiring emergency RBT.Baseline characteristics
Diabetes mellitus, hypertension, smoking, hyperlipidaemia,
chronic obstructive pulmonary disease, chronic renal
insufficiency, history of coronary artery disease, and history
of chronic heart failure were defined on the basis of clini-
cian diagnosis according to contemporary guidelines.
Type of surgery was classified on the basis of level of
surgery-specific risk according to ACC/AHA guidelines
(intermediate risk: carotid surgery; high risk: aortic surgery
and peripheral surgery).
Anaemia, bleeding, and blood transfusion
Anaemia was used as the exposure variable and was defined
as a haemoglobin value less than 9.0 g/dL within 7 days
after surgery. Severely anaemic patients (haemoglobin
<7.0 g/dL) were excluded from the study. These thresholds
were defined in keeping with the Transfusion Requirements
in Critical Care (TRICC) trial16 and subsequent expert
recommendations17 suggesting that, in the absence of
acute bleeding, haemoglobin levels of 7.0e9.0 g/dL are
well tolerated by most critically ill patients and that
a transfusion threshold of 7.0 g/dL is appropriate. The
lowest postoperative haemoglobin level prior to the first
transfusion or, for the non-transfused patients, the lowest
haemoglobin level during this time period were used to
categorize anaemia. Haemoglobin was measured before
surgery, soon after surgery and every 24 h for 7 days, and
when clinically indicated. We used haemoglobin level
because of the poor predictive value of haematocrit for
erythrocyte deficits after extensive elective vascular
operations.18
Postoperative bleeding severity was defined according to
the Thrombolysis In Myocardial Infarction (TIMI) study
classification. Minor bleeding was defined as haemoglobin
decrease of 3 g/dL or less, major bleeding as haemoglobin
decrease of 5 g/dL or more.19
Postoperative RBT was defined as a transfusion occur-
ring within 7 days after vascular surgery, and was deter-
mined at the discretion of each patient’s physician. There
was no haemoglobin level that mandated RBT. Data on the
number of units transfused, as well as the date and type or
blood product used, were recorded for each patient. At
our institution information on transfusion is accurately
documented as per national and institutional guidelines;
monitoring and quality control for RBT practice are in
place, and all patients gave written informed consent for
transfusion.
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Follow-up was provided by review of hospital charts,
telephone interview, death certificates, and autopsy
reports (if available), which were assessed by two inde-
pendent investigators who were unaware of the patients’
history, laboratory examinations, and aim of the study
(A.M. and A.D.G.). The main dependent variable was
death through 30 days; secondary endpoints were
myocardial infarction through 30 days, and the composite
endpoint death or myocardial infarction through 30 days.
Myocardial infarction was clinically and independently
diagnosed by pre-specified criteria using the new Amer-
ican College of Cardiology/European Society of Cardiology
(ACC/ESC) definition which requires a typical rise and
gradual fall of troponin values when either the setting,
clinical or electrocardiographic findings suggest the pres-
ence of acute ischaemia.20 In case of disagreement, the
matter was solved by consensus. Cardiac troponin I was
measured with the Stratus CS STAT Fluorimetric Analyzer
(Dade Behring Inc., Newark, DE) on the first, second and
third postoperative day in all patients regardless of clin-
ical setting as previously described.15 During follow-up
cardiac troponin I measurements were left to the discre-
tion of the treating physician but in most cases, values
were obtained if there were signs or symptoms suggestive
of ischaemia. The minimum detectable concentration is
with the Dade CS assay is 0.03 ng/mL and the upper
reference limit (99th percentile of the reference range) is
0.07 ng/mL. At the time of this study in our institute, the
lowest concentration with coefficient of variation <10%
was 0.10 ng/mL and this level of increase was used to
define troponin elevations.Statistical analysis
Baseline characteristics were compared across groups using
c2 tests for categorical variables or Fisher’s exact test,
whereas the t-test was used to compare continuous vari-
ables; variables with highly skewed distribution were
compared by the ManneWhitney non-parametric test.
Logistic regression models were used to identify the base-
line predictors of postoperative RBT and to calculate the
propensity to receive transfusion. This propensity score was
used as a covariate for multivariable adjustment. The
predicted probability for transfusion was calculated using
the following variables: age, sex, high-risk surgery, dia-
betes mellitus, hypertension, smoking, hyperlipidaemia,
previous coronary disease, chronic heart failure, renal
insufficiency, chronic obstructive pulmonary disease, and
bleeding.
The predicted probability for the risk of death was
calculated using the following variables: age, sex, diabetes
mellitus, hypertension, smoking, hyperlipidaemia, previous
coronary disease, chronic heart failure, renal insufficiency,
chronic obstructive pulmonary disease, high-risk surgery,
perioperative beta-blockers, bleeding, postoperative
anaemia, and preoperative haemoglobin. This propensity
score then was used for further multivariable adjustment
given there were differences in some medical co-variants
associated with increased risk.KaplaneMeier analysis was used to show 30-day
mortality among patients who did and did not receive RBT;
the log-rank test was used to compare the two groups. Cox
proportional hazard regression models were used to
examine the unadjusted and adjusted hazard ratio (HR) and
95% confidence interval (CI) for events through 30 days
among patients who received RBT compared to those who
did not receive RBT (referent). By using this model,
patients who were transfused after the occurrence of the
event were classified as not transfused. Because the
exposure to RBT was not random, several multivariable
models were created in order to account for potential
confounders including confounding by indication. The first
model incorporated preoperative data (we included vari-
ables with p < 0.10 at univariate analysis and age and
gender were forced into the model); the second was
adjusted for age, sex, surgical risk, and bleeding; the third
model was adjusted for the propensity to undergo trans-
fusion; and finally in a last model we adjusted for the
overall propensity score for death.
The interactions of RBT and anaemia, RBT and bleeding,
and RBT and history of coronary artery disease were tested
in the Cox models and multivariable adjustments for
propensity scores were performed. All tests were two-
sided, and for all analyses, p < 0.05 was considered
statistically significant. Analyses were carried out by using
software SPSS version 11.0 for Windows (SPSS Institute
Inc., Chicago, IL, USA) and STATA version 8.0 (College
Station, TX, USA).
Results
Three hundred and fifty-nine patients (mean age
70.0  9.1 years, 96 [26.7%] women) were included in the
study; 158 (44.0%) underwent intermediate risk vascular
surgery (carotid surgery) and 201 (56.0%) high risk vascular
surgery (150 infra-inguinal and 51 aortic surgery).
Blood transfusion
Of study patients, 95 (26.5%) received at least one unit of
red blood cells, 65 (18.1%) patients received RBT intra-
operatively, 62 (17.3%) after surgery, and 32 (8.9%) at both
times. Compared with those who did not receive blood,
patients who received a RBT had more medical co-
morbidities at presentation, especially chronic heart failure
and chronic renal insufficiency. Furthermore, patients who
received RBT were more likely to have undergone high-risk
surgery. Particularly, among transfused patients carotid
surgery was performed in 4.2% of cases, infra-inguinal
intervention in 60.0% and aortic surgery in 35.8%; among
non-transfused patients carotid surgery was performed in
58.3% of cases, infra-inguinal intervention in 35.2% and
aortic surgery in 6.4% (p < 0.001). High-risk surgery had
more postoperative bleeding and lower postoperative
haemoglobin values. Only two patients had postoperative
haemoglobin <7 g/dL and were not included in the study.
About 53% of patients who underwent RBTwere classified as
having anaemia vs. 9% of those who did not receive RBT
(p < 0.001). (Table 1) The mean number of units transfused
was 3.3  2.3 (range 1e16). Patients who underwent RBT
Table 1 Characteristics and odds ratios of patients who did, compared to those who did not (referent) receive RBT
Characteristics No transfusion
(NZ 264)
Transfusion
(NZ 95)
OR
(95% CI)
p
Mean age  SD 69.9  9.0 70.2  9.6 1.00 (0.98e1.03) 0.795
Women (%) 69 (26.1) 27 (28.4) 1.12 (0.66e1.89) 0.666
Pre-operative data
Diabetes mellitus (%) 96 (36.4) 41 (43.2) 1.33 (0.82e2.14) 0.243
Hypertension (%) 202 (76.5) 73 (76.8) 1.02 (0.58e1.78) 0.949
Smoking (%) 146 (55.3) 53 (55.8) 1.02 (0.64e1.63) 0.935
Hyperlipidaemia (%) 56 (21.2) 14 (14.7) 0.64 (0.34e1.22) 0.174
History of coronary disease (%) 74 (28.0) 22 (23.2) 1.45 (0.77e1.34) 0.358
Prior chronic heart failure (%) 51 (19.3) 28 (29.5) 1.74 (1.02e2.99) 0.042
Chronic renal insufficiency (%) 42 (15.9) 37 (38.9) 3.37 (1.99e5.72) <0.0001
Chronic obstructive lung disease (%) 68 (25.8) 31 (32.6) 1.40 (0.84e2.32) 0.200
Intra-operative and postoperative data
High-risk surgery (%) 110 (41.7) 91 (95.8) 3.17 (2.23e4.43) <0.0001
Perioperative beta-blockers 163 (61.7) 44 (46.3) 0.53 (0.33e0.85) 0.010
Minor or major bleeding vs. no bleeding 26 (9.8) 51 (53.7) 10.6 (6.00e18.79) <0.0001
Major bleeding 4 (1.5) 8 (8.6) e e
Mean lowest postoperative haemoglobin, g/dL  SD 11.5  1.7 9.2  1.7 0.48 (0.40e0.57) <0.0001
Postoperative anaemia (%) 25 (9.5) 50 (52.6) 10.62 (5.97e18.90) <0.0001
Number of total blood unit transfused, median
(25the75th percentile)
e 3 (2e4) e e
Length of hospital stay (days), median (25the75th percentile) 5 (4e9) 12 (9e18) 1.14 (1.10e1.19) <0.0001
Admission to ICU (%) 20 (7.6) 40 (42.1) 8.87 (4.81e16.35) <0.0001
Length of stay in ICU (days), median (25the75th percentile) 1 (1e2) 1 (1e5) 1.35 (0.93e1.94) 0.085
OR, odds ratio; CI, confidence interval; ICU, intensive care unit.
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who did not undergo RBT and were more likely to require
admission to an intensive care unit (all p < 0.001).
Blood transfusion and events
RBT was associated with a significantly increased risk of
30-day events. Fig. 1 shows the KaplaneMeier curves forFigure 1 KaplaneMeier cumulative incidence of 30-day
death among patients who did and did not receive RBT.30-day cumulative incidence of death among patients who
did and did not receive RBT. Patients who received RBT had
a higher risk of death than patients who did not receive RBT
(log-rank p < 0.0001).
At 30 days 20 had patients died, and 38 experienced
acute myocardial infarction. Compared with patients who
did not undergo RBT, patients who received RBT had
a significantly increased hazard for 30-day death (HR 11.72,
95% CI 3.92e35.10; p < 0.0001), myocardial infarction (HR
3.32, 95% CI 1.75e6.27; pZ 0.0003), and for the composite
endpoint of myocardial infarction or death (HR 4.02 95% CI
2.23e7.27; p < 0.0001). These associations remained even
after adjusting for relevant preoperative characteristics
including age, gender, chronic heart failure, and chronic
renal insufficiency (Table 2). The strong association
between RBT and 30-day outcomes persisted after adjust-
ing for high-risk surgery and bleeding (HR 7.81, 95% CI
2.32e26.32; pZ 0.001 for death; HR 3.14, 95% CI 1.41e
7.01; pZ 0.005 for myocardial infarction; HR 3.98, 95% CI
1.91e8.27; pZ 0.0002 for the composite of death or
myocardial infarction). Similar results were obtained after
adjusting for preoperative haemoglobin and intensive care
unit (ICU) stay.
In order to account for other possible confounders we
calculated the propensity to receive RBT with logistic
regression. After adjusting for the propensity to undergo
transfusion, patients who received RBT remained at higher
risk of 30-day death compared to those who did not receive
RBT (Table 2). A final propensity score for death was
Table 2 Frequency of 30-day events and unadjusted and adjusted hazard ratios for events through 30 days among patients
who did compared to those who did not (referent) receive RBT
Outcomes No transfusion
(NZ 264)
Transfusion
(NZ 95)
p Unadjusted HR
(95% CI)
Adjusteda HR
(95% CI)
Adjustedb HR
(95% CI)
p p p
30-Day events (%)
Death 4 (1.5%) 16 (16.8%) <0.0001 11.72 (3.92e35.10) 7.30 (2.39e22.28) 5.38 (1.45e20.0)
<0.0001 0.0004 0.012
Myocardial infarction 18 (6.8%) 20 (21.1%) 0.0001 3.32 (1.75e6.27) 2.19 1.13e4.26 2.23 (0.98e5.09)
<0.0001 0.021 0.056
Myocardial infarction or death 19 (7.2%) 26 (27.4%) <0.0001 4.02 (2.23e7.27) 2.76 (1.49e5.12) 3.07 (1.43e6.59)
<0.0001 0.001 0.004
HR, hazard ratio.
a Adjusted for relevant preoperative characteristics: age, gender, chronic heart failure, and chronic renal insufficiency.
b Adjusted for transfusion propensity. The predicted probability for transfusion was calculated using the following variables: age, sex,
surgery risk, diabetes, hypercholesterolaemia, smoking, hypertension, hyperlipidaemia, previous coronary disease, chronic heart
failure, renal insufficiency, chronic obstructive pulmonary disease, and bleeding.
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operative data and the strong association between RBT and
30-day death remained significant after adjustment for this
propensity score (HR 5.45, 95% CI 1.77e18.00; pZ 0.003).
There was a significant association between the number
of units of packed red cells transfused and 30-day death
(HR 1.31, 95% CI 1.20 to1.41; pZ 0.014), myocardial
infarction (HR 1.26, 95% CI 1.16e1.36; pZ 0.017), and the
composite endpoint of death or myocardial infarction (HR
1.26, 95% CI 1.18e1.78; pZ 0.010). No significant inter-
action was detected between RBT and bleeding and
between RBT and history of coronary disease in predicting
events.
Transfusion occurred on average 1.0  2.0 days after
surgery. Only five patients had postoperative troponin
elevation before receiving transfusion, exclusion of these
patients from the analysis did not change the results.
The increased risk of death, myocardial infarction, and
the composite endpoint myocardial infarction or death was
maintained in the long term. After a mean follow-up of
16.3  9.0 months HR was 4.02, 95% CI 2.24e7.87,
p < 0.001 for death; HR 2.02, 95% CI 1.15e3.57, pZ 0.015
for myocardial infarction; HR 2.67, 95% CI 1.71e4.18,
p < 0.001 for the composite endpoint death or myocardial
infarction.
Transfusion and postoperative anaemia
There was a significant interaction between RBT and post-
operative anaemia (p < 0.01). Therefore, we stratified the
patients according to the presence or absence of anaemia
(Table 3). Among study patients 75 (20.9%) had anaemia.
Among patients without anaemia, those who received RBT
were more likely to have renal failure, to have undergone
high-risk surgery, to have developed postoperative
bleeding, and less likely to receive perioperative beta-
blockers (all p < 0.05). Among patients with anaemia,
transfused patients were more likely to have undergone
high-risk surgery and to have developed postoperative
bleeding, but did not differ significantly for other
characteristics.In patients without anaemia, RBTwas associated with an
almost 20-fold increased risk of 30-day death (HR 19.20,
95% CI 3.99e92.45; pZ 0.007) and a five-fold increased risk
of the composite of death or myocardial infarction (HR
5.05, 95% CI 2.23e11.44; pZ 0.0001). Conversely, in
patients with anaemia, there was no significant association
between RBT and 30-day events (Table 4). In multivariable
propensity score analyses, after adjusting for the predicted
probability to undergo RBT the relation between RBT and
30 days events did not change. Indeed, patients without
anaemia had a significantly increased risk of 30-day death,
myocardial infarction, and the composite of death or
myocardial infarction (Table 3). After adjusting for the
predicted probability for death, RBT remained significantly
associated with an increased risk of 30-day death (HR
11.59, 95% CI 2.29e58.73; pZ 0.003) and death or
myocardial infarction (HR 3.80, 95% CI 1.58e9.18;
pZ 0.003) among patients without anaemia, but not
among patients with anaemia (HR 1.07, 95% CI 0.21e5.45;
pZ 0.936, and HR 0.66, 95% CI 0.25e1.73; pZ 0.400,
respectively).
Discussion
The present study suggests that, in elective major vascular
surgery, perioperative RBT is associated with a significantly
increased risk of 30-day death, myocardial infarction, and
the composite of death or myocardial infarction among
non-anaemic clinically stable patients preoperatively risk-
stratified and treated according to the ACC/AHA guidelines
for non-cardiac surgery. This association was independent
of baseline characteristics, surgical risk, bleeding, pres-
ence of anaemia, and propensity to receive transfusion.
Patients who received RBT had a significantly longer
hospital stay. In contrast, our data indicate no association
between RBT and events through 30 days among anaemic
subjects. These data suggest caution against the use of RBT
in stable patients with higher levels of postoperative
haemoglobin.
Postoperative anaemia is a frequent complication of
vascular surgery and it is associated with a significantly
Table 3 Baseline characteristics among patients who did and did not receive RBT by anemia
Baseline characteristics No anaemia (haemoglobin 9 g/dL) (NZ 284) Anaemia (haemoglobin <9 g/dL) (NZ 75)
No transfusion
(NZ 239)
Transfusion
(NZ 45)
p No transfusion
(NZ 25)
Transfusion
(NZ 50)
p
Mean age  SD 70.0  9.1 70.2  9.1 0.837 70.1  9.7 69.0  9.9 0.716
Women (%) 60 (25.1) 8 (17.8) 0.291 9 (36.0) 19 (38.0) 0.866
Pre-operative data
Diabetes mellitus (%) 88 (36.8) 13 (28.9) 0.308 8 (32.0) 28 (56.0) 0.051
Hypertension (%) 185 (77.4) 32 (71.1) 0.362 17 (68.0) 41 (82.0) 0.172
Smoking (%) 134 (56.1) 26 (57.8) 0.832 12 (48.0) 27 (54.0) 0.624
Hyperlipidaemia (%) 48 (20.1) 6 (13.3) 0.290 8 (32.0) 8 (16.0) 0.111
History of coronary disease (%) 68 (28.5) 9 (20.0) 0.242 6 (24.0) 13 (26.0) 0.851
Prior chronic heart failure (%) 45 (18.8) 11 (24.4) 0.385 6 (24.0) 17 (34.0) 0.861
Chronic renal insufficiency (%) 36 (15.1) 14 (31.1) 0.010 6 (24.0) 23 (46.0) 0.065
Chronic obstructive
pulmonary disease (%)
61 (25.5) 14 (31.1) 0.435 7 (28.0) 17 (34.0) 0.600
Intra-operative and postoperative data
High-risk surgery (%) 99 (41.4) 44 (97.8) <0.0001 11 (44.0) 47 (94.0) <0.0001
Perioperative beta-blockers (%) 150 (62.8) 20 (44.4) 0.021 13 (52.0) 24 (48.0) 0.744
Bleeding (%) 21 (8.8) 17 (37.8) <0.0001 5 (20.0) 34 (68.0) <0.0001
316 F. Bursi et al.increased risk of cardiac morbidity.1 The usual treatment is
RBT.2,21 Indeed, patients undergoing vascular surgery are at
risk for the adverse consequences of anaemia because of
the high prevalence of underlying coronary disease.22
Anaemic patients with coronary disease are at increased
risk3 because the compensatory mechanisms to anaemia
may be impaired, resulting in risk of oxygen deprivation to
vital organs.9 However, although previous observational
studies have suggested that vascular surgery patients are
less tolerant to anaemia,1 there is a lack of evidence to
indicate that RBT improves outcomes in this population.6
Our study demonstrates that RBT after major vascular
surgery is associated with an increased hazard for 30-day
death and acute myocardial infarction when used inTable 4 Hazard ratio for events through 30 days for patients wh
stratified by the presence of anaemia
No anaemia (NZ 284)
No transfusion
(NZ 239)
Transfusion
(NZ 45)
HR
(referent)
HR (95% CI) Adju
(95%
p p
30-Day death 1 19.20
(3.99e92.45)
18.7
(3.12
0.007 0.001
30-Day myocardial
infarction
1 3.49
(1.35e9.00)
2.66
(0.86
0.010 0.089
30-Day myocardial
infarction or death
1 5.05
(2.23e11.44)
4.53
(1.69
0.0001 0.00
a Adjusted for the propensity to undergo transfusion.patients who are not anaemic. Such an association held
even after adjustment for the influence of several vari-
ables, including preoperative characteristics, surgical risk,
postoperative bleeding, anaemia, and the propensity for
RBT. The consistency of our findings through different
outcomes and with multiple levels of adjustments under-
scores the robustness of our results. Our findings fully
support and extend to vascular surgery patients the
conclusion by the Anemia and Blood Transfusion in the
Critically Ill (CRIT)23 and the Anemia and Blood Transfusion
in Critical Care (ABC)24 studies. In these prospective, mul-
ticentre, cohort studies of intensive care unit patients,
allogenic RBTwere independently associated with mortality
particularly when more than 2 red blood cell units wereo did compared to those who did not undergo RBT (referent)
Anaemia (NZ 75)
No transfusion
(NZ 25)
Transfusion
(NZ 50)
steda HR
CI)
HR
(referent)
HR (95% CI) Adjusteda HR
(95% CI)
p p
e112.1)
1 2.35
(0.51e10.88)
0.64
(0.13e3.18)
0.274 0.642
e8.24)
1 0.92
(0.36e2.29)
0.78
(0.24e2.58)
0.851 0.228
e12.12)
1 1.06
(0.43e2.59)
0.83
(0.26e2.60)
3 0.904 0.745
Perioperative Transfusions in Vascular Surgery 317transfused. More recently Rao et al.25 demonstrated in the
setting of acute coronary syndromes that 30-day mortality
was almost 4 times higher in patients who did compared
with those who did not undergo RBT.
It may be that RBT does not augment oxygen
delivery26,27 or that RBT units during preparation and
storage undergo changes that contribute to decrease tissue
oxygen delivery.28,29 Moreover, the overall benefits of RBT
are related to patients’ capacity to compensate for
anaemia which may already be adequate in patients with
higher haemoglobin levels. In our study the association
between RBT and events appeared to be independent of
the presence of clinically detectable history of coronary
disease.
These findings are in agreement with recent observa-
tions. Rao et al. reported that the increased risk of death
after RBT in patients with acute coronary syndrome
occurred especially among patients with a higher haema-
tocrit level.25 Bush et al.30 preoperatively randomized 99
patients undergoing elective aortic and infrainguinal
surgery to receive either a liberal transfusion strategy
(maintaining a haemoglobin level of 10.0 g/dL) or
a restrictive strategy (transfusion only for haemoglobin
level 7.0 g/dL). In an intention-to treat analysis, there
was no difference in myocardial ischaemia, myocardial
infarction, or death between the strategies.
The mechanism whereby RBT worsens outcome in
vascular surgery patients is beyond the scope of this study.
RBT may have a number of unexpected consequences
including activation of inflammatory pathways,31 infec-
tion,6 vasoconstriction, and platelet aggregation.32 Of
interest, our patients were likely to have diffuse distal
coronary disease given the high prevalence of diabetes,
hypertension, and chronic renal insufficiency. In these
patients the prothrombotic properties of RBT may be
enhanced33 and thus RBT may actually impair oxygen
delivery in some patients and induce myocardial
ischemia.25
For patients with haemoglobin values >9 g/dL, the
approach should focus on implementing blood conservation
strategies, reducing perioperative blood loss, and
improving fluid management, and by identifying optimal
targets for transfusion triggers.34,35 For patients who are
more anaemic, it may well be that with larger data sets,
RBT might be found to be of benefit but even in this subset,
from our data, it appears that there are likely contrasting
risks that should result in cautious RBT and a reliance on the
other measures suggested above as well whenever possible.Limitations
Our study was a retrospective analysis of consecutive stable
patients undergoing elective major vascular surgery who
had been prospectively risk stratified at one centre.
However, it is challenging to perform a trial whereby
subjects are randomly assigned to transfusion both intra-
and postoperatively as demonstrated in the only relatively
small-sized trial published by Bush et al.30 where the
randomization was abandoned in case of complicated intra-
or postoperative course such as when there was evidence of
ischaemia. Although several models were created tocontrol for possible confounders, it is possible that some
unmeasured variables might have influenced the results.
Conclusion
In the setting of major vascular surgery, RBT is associated
with a significantly increased risk of 30-day death,
myocardial infarction, or both. RBT was particularly harm-
ful in patients without postoperative anaemia (haemoglo-
bin 9.0 g/dL), with a fourfold increased risk of 30-day
death, and we could not show significant protection even in
patients with lower haemoglobin levels. Our findings
caution against the use of RBT in stable patients after
elective major vascular surgery especially if they have
lesser degree of anaemia, and underscore the need for
a specifically designed randomized trial.
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